Center for Drug Design, College of Pharmacy , University of Minnesota , Minneapolis , Minnesota 55455 , United States.
Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases , National Institutes of Health , Bethesda , Maryland 20892 , United States.
J Med Chem. 2019 Mar 14;62(5):2814-2829. doi: 10.1021/acs.jmedchem.9b00144. Epub 2019 Mar 4.
Inhibitors of human p97 (also known as valosin-containing protein) have been actively pursued because of their potential therapeutic applications in cancer and other diseases. However, covalent and irreversible p97 inhibitors have not been well explored. Herein, we report our design, synthesis, and biological evaluation of covalent and irreversible inhibitors of p97. Among an amide and a reverse amide series we synthesized, we have identified a p97 inhibitor whose functional irreversibility has been established both in vitro and in cells. Also importantly, mass spectrometry reveals three potential cysteine residues labeled by this compound, and mutagenesis together with computer modeling suggests Cys522 as a major site, which when modified, could compromise the function of p97. Taken together, this new inhibitor may provide a template for designing more potent p97 inhibitors with covalent and irreversible characteristics.
由于其在癌症和其他疾病中的潜在治疗应用,人类 p97(也称为含有缬氨酸蛋白)的抑制剂一直受到积极研究。然而,共价和不可逆的 p97 抑制剂尚未得到充分探索。在此,我们报告了我们对 p97 的共价和不可逆抑制剂的设计、合成和生物学评价。在我们合成的酰胺和反向酰胺系列中,我们已经确定了一种 p97 抑制剂,其体外和细胞内的功能不可逆性已经得到证实。同样重要的是,质谱揭示了该化合物标记的三个潜在半胱氨酸残基,而突变和计算机建模表明 Cys522 是主要位点,修饰后可能会影响 p97 的功能。总之,这种新的抑制剂可能为设计具有共价和不可逆特性的更有效的 p97 抑制剂提供模板。